BGN Technologies

BGN Technologies is the technology transfer company of Ben-Gurion University, sitting at the center of the Negev’s growing technology ecosystem. The Beer Sheva location matters more than it sounds. The university and its surrounding research institutions have become a meaningful node in Israeli technology, particularly in cybersecurity, AI, and increasingly in bio-convergence and healthcare.

The thesis is built around commercializing Ben-Gurion University research and supporting the broader Negev innovation ecosystem. In healthcare, the focus runs across biotech, digital health, and AI/ML applications, with portfolio activity touching medical devices, diagnostics, computational biology, and health software. AI shows up frequently in line with the university’s cybersecurity and computer science strengths, which translate naturally into clinical AI, medical imaging, and data-intensive healthcare research.

Checks fall below two hundred and fifty thousand dollars at the Pre-Seed and Seed stages, structured to support spinouts and early commercialization rather than to lead institutional rounds. Geography is anchored in companies emerging from Ben-Gurion University and from the broader Negev technology ecosystem, with portfolio companies typically targeting global markets in the US and Europe. BGN Technologies is positioned as a foundational partner that bridges academic research and institutional venture capital, and successful spinouts are expected to attract follow-on capital from external investors.

The team operates with the discipline of a tech-transfer organization that understands its dual role as IP holder and early-stage backer. Founders work directly with commercialization staff and the university’s research community, and the engagement is substantive on questions of IP structuring, licensing, and the translation of academic work into a commercial product. The diligence is grounded in technical and scientific analysis, with attention to commercial credibility and the realistic path to follow-on funding.

In practice, BGN Technologies offers a bundle that is difficult to replicate from outside the university system. It owns or co-owns the foundational IP, it can structure the licensing and spinout, and it can deploy capital at the earliest stage. The fund is direct about scope. It does not invest in companies unaffiliated with Ben-Gurion University or the Negev research ecosystem, and the relationship structure is institutional rather than conventional. For academic founders coming out of Ben-Gurion in biotech, digital health, AI healthcare, or adjacent areas, BGN is the natural first partner. The fund is also constructive about handoffs to external venture investors and treats that as part of its mandate rather than a loss of control. Founders who engage well tend to come out with stronger IP positions, more credible commercial structures, and access to a Negev research ecosystem that is increasingly recognized as one of the more interesting concentrations of deep-tech talent in Israel.